ELN European LeukemiaNet

European Leukemia Information Center - ELIC

Newsletter no. 20 April/May 2014

CML Naples Fellows Day 2014

On May 5-6, the 6th Naples Fellows Day is held in Naples, Italy. Focussing on current treatment paradigms and future perspectives, this meeting allows young hematologists to exchange knowledge with leading experts in chronic myeloid leukemia. Deadline to register is April 11, 2014. ▸ Link to registration

Impact of bureaucracy on patient care in clinical research

Over the past decade, cancer research bureaucracy has become a major burden for the initiation of clinical trials. Just recently, a critical paper on this issue has been published in the Journal of Clinical Oncology. Herein, David Steensma and Hagop Kantarjian rise the question if these increasing regulatory requirements are still proportional to the benefit for patient safety and trial quality. ▸ JCO. 2014;32(5):376-8.

Publications from the Network (selected)

Acute lymphoblastic leukemia

- Bassan R. Ph+ ALL: imatinib grows older with patients. Blood. 2014 Feb 6;123(6):801-3.
- Ben Abdelali R et al. SET-NUP214 is a recurrent γδ lineage-specific fusion transcript associated with corticosteroid/chemotherapy resistance in adult T-ALL. Blood. 2014 Mar 20;123(12):1860-3.
- Burmeister T et al. Germline variants in IKZF1, ARID5B, and CEBPE as risk factors for adult-onset acute lymphoblastic leukemia: an analysis from the GMALL study group. Haematologica. 2014 Feb;99(2):e23-5.
- Eefting M et al. Myeloablative T cell-depleted alloSCT with early sequential prophylactic donor lymphocyte infusion is an efficient and safe post-remission treatment for adult ALL. Bone Marrow Transplant. 2014 Feb;49(2):287-91.
- Piñana JL et al. Umbilical cord blood transplantation from unrelated donors in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica. 2014 Feb;99(2):378-84.

Acute myeloid leukemia

- Breccia M et al. Aberrant phenotypic expression of CD15 and CD56 identifies poor prognostic acute promyelocytic leukemia patients. Leuk Res. 2014 Feb;38(2):194-7.
- Bug G et al. Long-term results of a prospective randomized trial evaluating G-CSF priming in intensive induction chemotherapy followed by autologous stem cell transplantation in elderly patients with acute myeloid leukemia. Ann Hematol. 2014 Feb;93(2):193-202.
- Chilton L et al. Hyperdiploidy with 49-65 chromosomes represents a heterogeneous cytogenetic subgroup of acute myeloid leukemia with differential outcome. Leukemia. 2014 Feb;28(2):321-8.
- Fasan A et al. Rare coincident NPM1 and RUNX1 mutations in intermediate risk acute myeloid leukemia display similar patterns to single mutated cases. Haematologica. 2014 Feb;99(2):e20-1.
- Janin M et al. Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group. J Clin Oncol. 2014 Feb 1;32(4):297-305.
- Récher C et al. Long-term results of a randomized phase 3 trial comparing idarubicin and daunorubicin in younger patients with acute myeloid leukaemia. Leukemia. 2014 Feb;28(2):440-3.
- Stelljes M et al. Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis. J Clin Oncol. 2014 Feb 1;32(4):288-96.Uttenthal B et al. Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses. Br J Haematol. 2014 Feb;164(3):366-75.

- Thol F et al. Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications. Blood. 2014 Feb 6;123(6):914-20.
- Wetzler M et al. Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification. Haematologica. 2014 Feb;99(2):308-13.

Chronic myeloid leukemia

- Baccarani M et al. Moving towards patient-centered decision-making in chronic myeloid leukemia: assessment of quality of life and symptom burden. Haematologica. 2014 Feb;99(2):205-8.
- Efficace F et al. Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors. Leuk Res. 2014 Mar;38(3):294-8.
- Hehlmann R et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol. 2014 Feb 10;32(5):415-23.
- Hochhaus A. Optimizing tolerability of TKI therapy in CML. Blood. 2014 Feb 27;123(9):1284-5.
- Hughes TP et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood. 2014 Feb 27;123(9):1353-60.
- Malagola M et al. Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era. Am J Hematol. 2014 Feb;89(2):119-24.
- Rousselot P et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol. 2014 Feb 10;32(5):424-30.

Chronic lymphocytic leukemia

- Cortelezzi A et al. Bendamustine in combination with Ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial. Leukemia. 2014 Mar;28(3):642-8.
- Goede V et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014 Mar 20;370(12):1101-10.
- Kern W et al. Flow cytometric identification of 76 patients with biclonal disease among 5523 patients with chronic lymphocytic leukaemia (B-CLL) and its genetic characterization. Br J Haematol. 2014 Feb;164(4):565-9.
- Mauro FR et al. Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile. Leuk Res. 2014 Feb;38(2):198-203.
- Oakes CC et al. Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemia. Cancer Discov. 2014 Mar;4(3):348-61.
- de Wreede LC et al. Improved relapse-free survival after autologous stem cell transplantation does not translate into better quality of life in chronic lymphocytic leukemia: lessons from the randomized European Society for Blood and Marrow Transplantation-Intergroup study. Am J Hematol. 2014 Feb;89(2):174-80.

Myelodysplastic syndromes

- Bacher U et al. Investigation of 305 patients with myelodysplastic syndromes and 20q deletion for associated cytogenetic and molecular genetic lesions and their prognostic impact. Br J Haematol. 2014 Mar;164(6):822-33.
- Platzbecker U et al. Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients. Leukemia. 2014 Mar;28(3):696-8.

Myeloproliferative neoplasms

- Alchalby H et al. Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2014 Feb;20(2):279-81.

- Barbui T et al. Masked polycythemia vera diagnosed according to WHO and BCSH classification. Am J Hematol. 2014 Feb;89(2):199-202.
- Barosi G et al. Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: a consensus-based SIE, SIES, GITMO position paper. Leuk Res. 2014 Feb;38(2):155-60.
- Hasan S et al. Use of the 46/1 haplotype to model JAK2(V617F) clonal architecture in PV patients: clonal evolution and impact of IFNα treatment. Leukemia. 2014 Feb;28(2):460-3.
- Jaekel N et al. Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib. Bone Marrow Transplant. 2014 Feb;49(2):179-84.
- Massa M et al. Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib. Leukemia. 2014 Feb;28(2):449-51.
- Mesa RA et al. Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. Haematologica. 2014 Feb;99(2):292-8.
- Passamonti F et al. Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. Blood. 2014 Mar 20;123(12):1833-5.
- Randi ML et al. Pregnancy complications predict thrombotic events in young women with essential thrombocythemia. Am J Hematol. 2014 Mar;89(3):306-9.
- Rey J et al. Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France. Eur J Haematol. 2014 Feb;92(2):127-36.
- Verstovsek S et al. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer. 2014 Feb 15;120(4):513-20.

Stem cell transplantation

- Rasche L et al. EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoetic SCT. Bone Marrow Transplant. 2014 Feb;49(2):163-7.
- Rodrigues CA et al. Alternative donor hematopoietic stem cell transplantation for mature lymphoid malignancies after reduced-intensity conditioning regimen: similar outcomes with umbilical cord blood and unrelated donor peripheral blood. Haematologica. 2014 Feb;99(2):370-7.
- Ruutu T et al. Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. Bone Marrow Transplant. 2014 Feb;49(2):168-73.
- Uhlin M et al. Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation. Haematologica. 2014 Feb;99(2):346-52.
- Watz E et al. Analysis of donor and recipient ABO incompatibility and antibody-associated complications after allogeneic stem cell transplantation with reduced-intensity conditioning. Biol Blood Marrow Transplant. 2014 Feb;20(2):264-71.

Miscellaneous

- Milojkovic D et al. How I treat leukemia during pregnancy. Blood. 2014 Feb 13;123(7):974-84.
- Fu Y et al. Postallogeneic monitoring with molecular markers detected by pretransplant next-generation or Sanger sequencing predicts clinical relapse in patients with myelodysplastic/myeloproliferative neoplasms. Eur J Haematol. 2014 Mar;92(3):189-94.

New trials in the ELTR

CINC424A2104 (HARMONY) A Phase Ib, Open-label, Multi-center, Two-arm, Dose-finding Study to Assess Safety and Efficacy of the Oral Combination or INC424 (INC424) and BKM120 in Patients With Primary Myelofibrosis (PMF), Postpolycythemia Vera-myelofibrosis (PPV-MF), or Post-essential Thrombocythemia-myelofibrosis (PET-MF)

ELN Foundation
European LeukemiaNet

Support the ELN Foundation

European Leukemia Information Center
Dr. Nicola Gökbuget, Dr. Sina Hehn
University Hospital Frankfurt
Department of Medicine II | Theodor-Stern-Kai 7
60590 Frankfurt am Main | Germany

ELIC@em.uni-frankfurt.de | www.leukemia-net.org | unsubscribe